News Manchester joint venture will trial Morningside's digital he... The University of Manchester has formed a joint venture with Morningside to carry out clinical trials of various digital health technologies developed by the investment group's portfolio co
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.